Evaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07601464

Acronym

TERMOMIRNA

Enrollment

150

Registered

2026-05-22

Start date

2026-03-26

Completion date

2028-12-31

Last updated

2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocarcinoma

Keywords

hepatocarcinoma, liver cancer, microRNA, thermoablation

Brief summary

The main objectives of this research project concern the identification of microRNAs circulating and of serum metabolites predictive of treatment response in patients with early stage hepatocellular carcinoma undergoing locoregional treatment with thermoablation. In addition, the molecular mechanisms involved in reprogramming will be identified metabolic via bioinformatics analysis and pretreatment liver biopsy analysis and analysis of screening on patient-derived primary lines for personalized therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Inclusion criteria

* Age ≥ 18 * Diagnosis of hepatocarcinoma confirmed by radiology (LIRADS criteria/triphasic diagnostics) or by biopsy. * Indication for thermoablation treatment (for radiofrequency) based on the judgment of the hepatologist/surgeon. * Informed consent signed by the patient.

Exclusion criteria

* Presence of metastatic liver lesions of other origins. * History of liver transplant. * Severe, uncorrectable coagulopathy, contraindicating liver biopsy (where necessary) or ablative procedure. * Patient refusal to participate in the study or inability to obtain informed consent. * Pregnant women.

Design outcomes

Primary

Measure	Time frame	Description
circulant microRNA	At baseline, at 24 hours, 1 month, 3 months	micro-RNAs differentially expressed between the complete response and disease residue groups
tissue microRNA	At baseline	micro-RNAs differentially expressed between the complete response and disease residue groups
Metabolomic analysis	At baseline, 24 hours, 1 month, 3 months	Identification of circulating metabolites differentially expressed between the complete response and disease residue groups

Secondary

Measure	Time frame	Description
Relapse Free Survival	24 hours, 1 month, 3 months	0-1
Overall Survival	24 hours, 1 month, 3 months	0-1
Hepatocarcinoma recurrence	24 hours, 1 month, 3 months	Ecography

Countries

Italy

Contacts

CONTACTAndrea Boccatonda, MD

andrea.boccatonda@aosp.bo.it+39 0512143265

Outcome results